Neurotrophic keratitis: from the trigeminal ganglion to the cornea
Chapter from the "Corneal wound healing" course. Mechanistic framework drawn from the review "Corneal wound healing: a reading through epithelial-stromal interactions." All figures in this series are taken from the reference publication: Saad S, Abdelmassih Y, Saad R, Guindolet D, El Khoury S, Doan S, Cochereau I, Gabison EE. Neurotrophic keratitis: frequency, etiologies, clinical management and outcomes. Ocul Surf 2020;18(2):231-236. Iconography and clinical cases: course "Les Kératites Neurotrophiques" (Neurotrophic Keratitis), Pr E. Gabison, Tours 2018.
Neurotrophic keratitis (NK) is the clinical demonstration that corneal wound healing depends on the nerve as much as on the cell and the matrix. Trigeminal innervation does not only provide nociception: it delivers continuous trophic support — NGF, substance P, CGRP, PACAP, VIP — without which the epithelium no longer proliferates, migrates, or adheres.
One concept structures the whole chapter and predicts severity: the level of the lesion relative to the Gasserian ganglion. A pre-ganglionic or partial ganglionic lesion spares the cell body and the peripheral axon — sensitivity falls but trophic support persists, and the picture remains a superficial punctate keratitis. A post-ganglionic or total ganglionic lesion interrupts axonal transport of trophic factors: this is the neurotrophic ulcer.
The disease can then be read within the epithelial-stromal interaction framework of this course: the trophic deficit creates delayed healing (> 7 days), then a persistent epithelial defect (> 14 days) — the main risk factor for stromal melting; the basement membrane fails to mature, the epithelium and keratocytes enter direct contact, and the EMMPRIN/CD147 → MMP pathway tips the tissue toward keratolysis. NK is the clinical archetype of the lytic side of wound healing.
It is far more common than assumed — 11/10,000 patients — dominated by herpes (32.2%), iatrogenic causes (31.9%), central neurological causes (27.7%) and diabetes (10.5%). Visual prognosis depends on the initial Mackie stage, initial visual acuity and age. Three therapeutic targets structure management: limiting inflammation and iatrogenic injury, promoting epithelial healing, limiting stromal melting.
An eye that "melts" without pain: the very anesthesia that removes the symptom is precisely what deprives the cornea of its repair. This is the founding paradox of neurotrophic keratitis.
Corneal innervation: functional anatomy
A unique density and organisation
Fibers arising from the ophthalmic branch of the trigeminal nerve (V1) enter the stroma peripherally, lose their myelin sheath, run forward and successively form the sub-epithelial (sub-basal) plexus, intra-epithelial arcades, and then free nerve endings between epithelial cells. Nerve density is maximal centrally and decreases toward the periphery — which explains the preferential central or paracentral topography of neurotrophic lesions.
Functionally, 30% A-delta fibers (myelinated, fast-conducting) and 70% C fibers (unmyelinated) provide intense nociception, responding to mechanical, thermal and chemical stimuli (Müller et al., Exp Eye Res 2003).
Three functions, one too often overlooked
Corneal innervation provides a sensory function (defense), a reflex function (blinking, lacrimal secretion via the trigeminal-facial arc) and a trophic function. It is this last one that underlies the disease: nerve endings continuously release NGF, substance P, CGRP, PACAP and VIP, in a bidirectional dialogue — the epithelium and stroma in turn producing the NGF and growth factors required for the survival and regeneration of the nerves themselves.
Epithelium ↔ nerves ↔ stroma. Neurotrophic keratitis arises from the simultaneous interruption of these three arrows — hence the diagnostic delays: 37.9% of eyes in the series, with a mean delay of 38.8 days.
The key concept: pre- versus post-ganglionic
This is the major conceptual contribution of the field (Dhillon et al., Acta Ophthalmol 2016; Dua HS et al., Prog Retin Eye Res 2018), and the only element that allows severity to be predicted before the cornea is even examined.
The cell body of the sensory neuron sits in the trigeminal (Gasserian) ganglion. It synthesizes the neuromediators, which are then carried by anterograde axonal transport to the corneal nerve endings. The consequence is immediate:
- Pre-ganglionic lesion (upstream of the ganglion: nucleus, root, brainstem) or partial ganglionic lesion → the cell body and peripheral axon remain intact. Sensory transmission to the CNS is interrupted — the eye is hypoesthetic or anesthetic — but trophic support is preserved. The picture is typically limited to superficial punctate keratitis (stage I), slow-evolving and generally favorable.
- Post-ganglionic lesion (downstream: V1 branch, ciliary nerves, corneal nerves) or total ganglionic lesion → the peripheral axon degenerates, and transport of trophic factors ceases. This is the setting for the neurotrophic ulcer, the persistent defect and melting.
Faced with corneal hypoesthesia, the question "where is the lesion relative to the ganglion?" immediately orients the prognosis. A cerebellopontine angle tumor or a brainstem stroke (pre-ganglionic) will readily give chronic SPK; trigeminal thermocoagulation, skull-base surgery injuring V1, ophthalmic zoster or repeated keratoplasty (post-ganglionic) carry a risk of ulceration. This does not exempt from surveillance — but it does prioritize concern.
This framework also sheds light on a therapeutic finding developed in Chapter 18: RGTA works better in NK of central origin (thus often pre-ganglionic, with a preserved peripheral axon) than in herpetic NK (post-ganglionic, with a destroyed axon). The treatment's cellular target still exists in the former case.
Investigations
Esthesiometry — a frayed cotton wisp for screening, Cochet-Bonnet for quantification — remains the diagnostic gesture. In vivo confocal microscopy objectifies and quantifies sub-basal plexus rarefaction (Benítez del Castillo, IOVS 2007; Hamrah, Ophthalmology 2010; Labbé, IOVS 2012; Dhillon 2016; Stephan 2018). MRI has its place when the etiology is not obvious — the series includes the case of a 60-year-old woman in whom SPK with hypoesthesia discovered on preoperative cataract work-up led to the diagnosis of right trigeminal nucleus hypoplasia.
Pathophysiology: from delayed healing to keratolysis
Normal epithelial healing: a precise and fragile organisation
After epithelial injury, a latency phase of about 6 hours opens: cytoskeletal reorganization, changes in intercellular junctions, cleavage of hemidesmosomes and cell-matrix junctions, and apoptosis of the underlying keratocytes. Sheet migration, proliferation and finally stratification follow.
Two balances govern this process, and NK disrupts both:
- Cellular migration / proliferation balance. Harmonious healing requires that migrating cells do not proliferate: proliferation occurs outside the defect zone. This sequencing is orchestrated by the TGF-β (inhibits proliferation) / EGF (migration and proliferation) balance and by neurotrophic factors.
- Matrix synthesis / degradation balance. A transient extracellular matrix (fibrin, fibronectin, laminin, tenascin) is synthesized for focal adhesion and migration, then degraded by proteases (uPA/plasmin, MMP-1, MMP-9). Too little proteolysis: the cell stays stuck. Too much: it loses its support.
Delayed healing and persistent epithelial defect: the definitions that matter
Two time thresholds, to be remembered as they stand:
- Delayed healing: beyond 7 days.
- Persistent epithelial defect: beyond 14 days.
Delayed epithelial healing is the main risk factor for stromal melting and thinning. Identifying this delay as early as possible is the decisive prognostic act.
The switch to proteolysis: the EMMPRIN/MMP sequence
What follows is described in the course's general review, and NK is its purest clinical model:
- Trophic deficit → persistent epithelial defect.
- The epithelial basement membrane fails to regenerate — yet it is both the physical barrier to epithelial-stromal contact and the "valve" that controls TGF-β entry into the stroma (Wilson's model).
- Opening of direct epithelial-stromal interactions (DESI): keratocytes, which underwent apoptosis at the time of the initial injury, normally recolonize the anterior stroma behind a reformed basement membrane. With no basement membrane interposed — or even loss of Bowman's layer, which does not regenerate once destroyed — that same recolonization instead results in direct cell-cell contact with the epithelium: this is DESI, which is always pathological.
- EMMPRIN/CD147 comes into play and reverses the logic of TGF-β. On direct contact, EMMPRIN — itself under the control of TGF-β and EGF — simultaneously induces MMPs and myofibroblastic differentiation. TGF-β, anti-proteolytic as a diffusible signal, becomes pro-lytic: the result is a lytic myofibroblast, not a fibrotic one.
- Keratolysis → thinning → perforation, with a vicious circle maintained by collagen degradation products, which are chemotactic for neutrophils.
Historically, it was a collagenolytic activity identified as early as the late 1960s in explants of ulcerated corneas — and absent from healthy corneas — that opened up this field, before the identification of matrix metalloproteinases and their induction by epithelium-stroma interaction (Fini et al., JBC 2003; Gabison et al., Prog Retin Eye Res 2009).
An amplifier: dryness
Dryness is almost constant in NK — loss of the lacrimal reflex, reduced blinking, associated lagophthalmos. Tear film hyperosmolarity increases EMMPRIN and MMP-9, which cleave occludin at tight junctions and disorganize the epithelial barrier (Huet et al., Am J Pathol 2011). Dryness and trophic deficit therefore converge on the same molecular pathway — hence the clinical aphorism: "one ulcer may hide another," and the rule of testing sensitivity in any dry-looking keratitis that fails to heal.
A new concept: denervation induces a "functional limbal insufficiency"
An important experimental study (Okada Y. et al., Lab Invest 2018) shows that trigeminal denervation in mice does not merely slow wound closure: it alters the limbal stem cell compartment itself — loss of ABCG2 expression, a drop in pro-NGF, and collapse of proliferation (BrdU) at the periphery and limbus. Restoring TRPV4 signaling (via AAV) partially corrects the phenotype.
The concept of "functional limbal insufficiency" explains why some advanced NK cases take on the appearance of limbal insufficiency (superficial neovascularization, conjunctivalization, whorl keratopathy) without anatomical destruction of the limbus, and why they may be reversible if trophic support is restored. It counsels caution before offering limbal stem cell transplantation on a purely neurotrophic background.
Glossary of abbreviations used in this course
Scientific abbreviations and acronyms used throughout the 10 pages of this course, listed alphabetically.
No matching term.
- 95% CI
- 95% confidence interval
- AAV
- adeno-associated virus (gene-therapy viral vector)
- ABCG2
- ABCG2 transporter, a limbal stem-cell marker
- AMT
- amniotic membrane transplantation
- anti-VEGF
- anti-angiogenic treatment targeting VEGF
- ASC
- inflammasome adaptor protein (Apoptosis-associated Speck-like protein containing a CARD)
- BrdU
- bromodeoxyuridine, a cell-proliferation marker
- CCL2
- CCL2 chemokine, synonym of MCP-1; recruits circulating monocytes
- CCR2
- receptor for CCL2; marker of newly recruited monocytes/macrophages
- CD147
- cluster of differentiation 147; synonym of EMMPRIN and basigin
- CD163
- M2 macrophage marker; scavenger receptor for haemoglobin-haptoglobin
- CD206
- mannose receptor; marker of M2 polarization
- CD74
- cell-surface receptor for MIF
- CDVA
- corrected distance visual acuity
- CGRP
- calcitonin gene-related peptide
- CTGF
- connective tissue growth factor
- CX3CL1
- fractalkine, a chemokine involved in monocyte/macrophage recruitment
- CXCR2/CXCR4
- chemokine receptors, also receptors for MIF
- DAMP
- damage-associated molecular pattern
- DESI
- direct epithelial–stromal interaction
- EGF
- epidermal growth factor
- EGFR
- epidermal growth factor receptor
- EMMPRIN
- extracellular matrix metalloproteinase inducer; synonym of CD147
- ETDRS
- reference visual-acuity scale used in clinical research (Early Treatment Diabetic Retinopathy Study)
- FasL
- Fas ligand, an apoptosis-inducing protein
- FISH
- fluorescence in situ hybridisation
- GAG
- glycosaminoglycan(s)
- GM-CSF
- granulocyte-macrophage colony-stimulating factor
- GVHD
- graft-versus-host disease
- HGF
- hepatocyte growth factor
- HIF-3α
- hypoxia-inducible factor, 3-alpha subunit
- HMGB1
- high mobility group box 1, an alarmin released by injured cells (DAMP)
- IFN-γ
- interferon gamma
- IGF-1
- insulin-like growth factor 1
- IL-1
- interleukin-1
- iNOS
- inducible nitric oxide synthase
- IPAS
- inhibitory PAS domain protein
- KGF
- keratinocyte growth factor
- LASIK
- laser-assisted in situ keratomileusis
- LogMAR
- logarithmic visual-acuity scale
- LOX
- lysyl oxidase, a collagen cross-linking enzyme
- LPS
- bacterial lipopolysaccharide
- M1
- classically activated macrophage, pro-inflammatory profile
- M2
- alternatively activated macrophage, pro-resolving/reparative profile (subtypes M2a-M2d, M2eff)
- MEN2B
- multiple endocrine neoplasia type 2B
- MerTK
- receptor tyrosine kinase involved in efferocytosis
- MIF
- macrophage migration inhibitory factor
- MRI
- magnetic resonance imaging
- NGF
- nerve growth factor
- NK
- neurotrophic keratitis
- NLRP3
- NLRP3 inflammasome (NOD-, LRP- and pyrin domain-containing protein 3)
- NO
- nitric oxide
- NSAID
- nonsteroidal anti-inflammatory drug
- PACAP
- pituitary adenylate cyclase-activating polypeptide
- PAF
- platelet-activating factor
- PAMP
- pathogen-associated molecular pattern
- PDGF
- platelet-derived growth factor
- PED
- persistent epithelial defect
- PEDF
- pigment epithelium-derived factor
- PGE₂
- prostaglandin E2
- PRK
- photorefractive keratectomy (laser surface ablation)
- pro-NGF
- precursor form of NGF
- RGTA
- matrix-therapy ReGeneraTing Agent, e.g. Cacicol
- rhNGF
- recombinant human NGF (cenegermin)
- ROS
- reactive oxygen species
- Smad
- signalling proteins of the TGF-β pathway
- SPK
- superficial punctate keratitis
- sVEGFR-1
- soluble form of VEGF receptor-1 (= sFlt-1)
- sVEGFR-3
- soluble form of VEGF receptor-3
- TGF-β
- transforming growth factor beta
- TIMP
- tissue inhibitor of metalloproteinases
- TLR
- Toll-like receptor
- TNF-α
- tumour necrosis factor alpha
- TRPV4
- transient receptor potential vanilloid 4, a mechanosensitive ion channel
- uPA
- urokinase-type plasminogen activator
- V1
- ophthalmic branch of the trigeminal nerve
- VEGF
- vascular endothelial growth factor
- VEGF-C
- lymphangiogenic isoform of VEGF
- VIP
- vasoactive intestinal peptide
- YAP/TAZ
- Hippo pathway effectors, mechanosensors of matrix stiffness
- α-SMA
- alpha-smooth muscle actin, a myofibroblast marker